Canaccord Genuity Downgrades Regeneron Pharmaceuticals to Hold, Lowers Price Target to $720
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst John Newman has downgraded Regeneron Pharmaceuticals from Buy to Hold and lowered the price target from $953 to $720.
June 28, 2023 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals has been downgraded from Buy to Hold by Canaccord Genuity, with a lowered price target of $720.
The downgrade from Buy to Hold by Canaccord Genuity indicates a less optimistic outlook for Regeneron Pharmaceuticals. The lowered price target from $953 to $720 also suggests that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100